Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $130.00 short put and a strike $120.00 long put offers a potential 9.29% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $130.00 by expiration. The full premium credit of $0.85 would be kept by the premium seller. The risk of $9.15 would be incurred if the stock dropped below the $120.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 75.84 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Adesto Technologies: A Solid Internet of Things Play
Mon, 13 Apr 2020 20:58:01 +0000
The company has recovered from its Covid-19 fall and operates in a high-growth IoT industry with a strong client base Continue reading…
Johnson & Johnson has coronavirus vaccine candidate in works, but medical devices are likely to take a hit
Mon, 13 Apr 2020 19:34:00 +0000
Johnson & Johnson is, in many ways, the benchmark company for the performance of publicly traded, health-care companies.
Trading Johnson & Johnson Earnings – Here Are the Must-Know Levels
Mon, 13 Apr 2020 18:30:00 +0000
Johnson & Johnson will report first-quarter earnings on Tuesday. Here's what the charts say now for the stock.
Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result?
Mon, 13 Apr 2020 16:01:04 +0000
J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.
U.S. Stocks To Watch This Week
Mon, 13 Apr 2020 15:35:35 +0000
The first-quarter earnings season begins.
Also on Market Tamer…
Follow Us on Facebook